… benefit from erlotinib. To clarify the role of EGFR in the outcome of non–small-cell lung cancer,
we … of EGFR, and mutation status of the gene in a subgroup of patients in the BR.21 study. …

… to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs
survival in non–small-cell lung cancer after the failure of first-line or second-line chemotherapy. …

… patients with EGFR-negative tumours. In contrast, increasing severity of rash in erlotinib-treated
lung cancer patients was … cancer and head and neck cancer patients [44]. The median …

… Symptom improvement in lung cancer patients treated with erlotinib: quality of life
analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. …

… low in lung SCC. The aim of this study was to evaluate the status … erlotinib treatment and
EGFR mutation in lung SCC patients. Methods: We retrospectively enrolled lung cancer patients …

… patients with advanced LSQC treated with erlotinib monotherapy during January 2006 to
October 2011. We included lung cancer patients … , had history of erlotinib treatment, and had …

… Our objective was to assess the pharmacokinetics of erlotinib in a large patient population
with … and diarrhea) in patients with non-small cell lung cancer receiving single-agent erlotinib. …

… or placebo with gemcitabine and carboplatin or cisplatin followed by maintained erlotinib
or placebo in patients with stage IIIB/IV non-small-cell lung cancer. The study was undertaken …

Purpose Several cases have been reported in which central nervous system (CNS) metastases
of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. …

… erlotinib may enhance antitumor activity compared with either agent alone in non–small-cell
lung cancer (… plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC. …